GlassScriptPhysician profile
Rene Choi
NPI 1881038404
$21,006.27
in general payments reported to CMS, 2019-2025
21 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,514 · 2021: $5,132 · 2022: $2,618 · 2023: $1,256 · 2024: $10K · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,922 · Food and Beverage: $2,909 · Travel and Lodging: $812 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,922.00 |
| Food and Beverage | $2,909.21 |
| Travel and Lodging | $812.11 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,454.62 | 2022-2025 | Ozurdex |
| Eyepoint US, INC. | $6,104.98 | 2021-2023 | |
| Carl Zeiss Meditec, INC. | $1,459.07 | 2020 | |
| Alimera Sciences, INC. | $1,302.06 | 2020-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $536.22 | 2022-2024 | Xipere |
| Mallinckrodt Hospital Products INC. | $484.82 | 2020-2024 | Acthar |
| Genentech USA, INC. | $461.49 | 2021-2025 | Vabysmo, Susvimo |
| Coherus Oncology, INC. | $357.45 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $267.68 | 2022-2025 | Eylea Hd, Eylea |
| Sandoz INC. | $155.04 | 2024 | Cimerli |
| Allergan, INC. | $91.84 | 2021 | |
| Rayner Intraocular Lenses Limited | $66.10 | 2025 | Omidria |
| Dutch Ophthalmic, USA | $65.64 | 2021 | |
| Apellis Pharmaceuticals, INC. | $49.11 | 2022-2024 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.00 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.81 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $23.27 | 2021 | |
| Biogen, INC. | $17.10 | 2023 | |
| Eyevance Pharmaceuticals LLC | $13.52 | 2021 | |
| Ani Pharmaceuticals, INC. | $13.45 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.